The SAFE Drugs Act (S.3794): what the Senate compounding bill would change, and what got cut before it left committee
If you get a compounded GLP-1 or peptide from a telehealth service, the pharmacy that filled it may well be in another state. A bipartisan Senate bill aimed at exactly that setup is now waiting for a floor vote. It's called the SAFE Drugs Act of 2026, and the version that came out of committee in July is much narrower than the one that went in. The changes say a lot about where Congress is on compounding right now.
Facts are as of November 8, 2026. Sources, with retrieval dates, are at the bottom.
Before you read on
- S.3794 was introduced February 5, 2026, by Sen. Jim Banks (R-Ind.) with Sen. Martin Heinrich (D-N.M.). [V]
- The Senate HELP Committee approved it 17-5 on July 22, 2026, after replacing the whole text with a substitute. It was placed on the Senate calendar on July 27. [V]
- The committee version would require 503ASection of federal drug law covering compounding by state-licensed pharmacies and doctors, usually for a prescription written for one patient. Glossary entry compounders who ship across state lines to report serious adverse events, report interstate volumes once a year above a threshold, and label products as not FDA-approved. [V]
- It has not passed the full Senate, and the House has not acted on it. It is not law. [V]
Two kinds of compounders, quickly
Federal law has two lanes. 503A covers state-licensed pharmacies and physicians who compound for individual patients with a prescription. 503BSection of federal drug law for outsourcing facilities: larger compounders that register with FDA and must follow drug-manufacturing quality rules. Glossary entry covers registered "outsourcing facilities" that can make larger batches and are held to factory-style quality rules. Our 503A bulks list explainer covers which ingredients the 503A lane may use. The SAFE Drugs Act mostly targets 503A.
What the bill said when it was introduced
The February version was ambitious. According to its text and the Congressional Research Service summary, it would have: [V]
- Rewritten "essentially a copy." A compounded drug would count as a copy of a commercial product if it shared any active ingredient and had no change, made for an identified patient, that the prescriber judged to make a significant difference.
- Set a 20-a-month cap on compounding such copies. CRS notes current FDA policy allows four such prescriptions a month.
- Added volume reports for compounders sending more than 20 such products a month to other states.
- Tightened 503B oversight, with a pre-production inspection for large outsourcing facilities and reinspection at least every two years.
- Let HHS reset the outsourcing-facility fee, now a fixed base amount in the law.
What survived the committee
On July 22, HELP Chair Bill Cassidy offered an amendment in the nature of a substitute, adopted by voice vote. The committee then approved the bill 17-5. [V] The reported text, dated July 27, strikes all five original sections. [V] What's left is two substantive sections, plus the short title.
1. Reporting. A 503A pharmacist or physician who sends compounded drugs out of state would have to pass along any serious adverse event report they receive. It would go to FDA, to their own state and to every state the products were sent to. [V] Anyone sending more than 5% of their yearly compounded output across state lines would also file an annual report by January 15. It would list their license details and the units shipped to each state, by product type and month. [V] Hospital pharmacies compounding for their own patients are exempt, and states keep the power to demand more. [V]
2. Labeling. Every 503A compounded product would carry a statement that it was compounded for an individual patient and has not been approved by FDA. It would also list FDA's MedWatch website and 1-800-FDA-1088 for reporting side effects. [V]
- 17-5HELP Committee vote, July 22, 2026 [V]
- 5%out-of-state share that would trigger annual reports [V]
- 2substantive sections in the committee version, plus its short-title section [V]
What got dropped
The new definition of "essentially a copy," the 20-a-month cap, the 503B inspection schedule and the fee change are all gone from the committee text. [V] Sen. Banks described the result at the markup as a compromise worked out with pharmacy associations and drug-safety groups, with some issues left for later, according to a markup summary. [S]
So the fight over how often a pharmacy can make a copy of an approved drug, the issue at the center of the compounded semaglutide and tirzepatide boom, is not settled by this bill. Our explainer on FDA's 30 telehealth warning letters shows how FDA is handling that issue under current law.
Heinrich put the case in one line in his statement after the vote: patients should know when a medicine isn't FDA-approved and may carry serious risks. [V]
Why peptide readers should care
Two threads meet here.
The HHS six-peptide policy runs through 503A. HHS's draft enforcement policy for six peptides covers 503A compounding for individual patients with a prescription, and its comment period closes November 13. [V] If both the policy and this bill took effect, compounded versions of those peptides shipped across state lines would carry the not-FDA-approved label, and serious side-effect reports would reach FDA and the states. [U] That's our reading of how the two texts would fit together. Neither is final. Our comment-period explainer tracks the docket.
Telehealth is mostly interstate. Banks's office tied the bill to the growth of compounding alongside telehealth and online prescribing. [V] The reporting and labeling rules would land hardest on pharmacies that fill for patients in many states, which is how most telehealth GLP-1 and peptide programs work. [U] For background, see our guide to how telehealth clinics work.
Three common mix-ups
"Congress passed a compounding crackdown." A committee approved it. The full Senate hasn't voted, and the House hasn't acted. [V]
"It caps compounded GLP-1s." The 20-a-month cap was in the February text and was dropped in committee. [V]
"It bans compounded peptides." Neither version bans any substance. The committee version adds reporting and a label. [V]
Limits and unknowns
- We didn't find a written committee report, and congress.gov says the bill was reported without one. So there's no official explanation of why each provision was cut. [V]
- We haven't confirmed a House companion bill or any scheduled floor time. [U]
- The 17-5 vote is from the HELP Committee's own markup page and press release. A separate markup summary listed it as 18-4, so we use the committee's figure. [V]
- How FDA would carry out the reporting system, including the "form and manner" left to HHS, would depend on later guidance if the bill passed. [V]
Peptide Policy Watch
The SAFE Drugs Act (S.3794): what the Senate compounding bill would change, and what got cut before it left committee
Printable checklist
What to ask at your next appointment
General questions drawn from this page, to take to a clinician or pharmacist who knows your health history.
- Is the medicine I'm getting compounded, or an FDA-approved product?
- Which pharmacy makes it, and in which state?
- If I have a side effect, who should I report it to?
- Does the label say whether it is FDA-approved?
Print view Select it, then use your browser’s Print command to print only this box.
What happens next
The bill sits on the Senate calendar as No. 524. It needs a floor vote, then House action, then a signature. Bills placed on the calendar often wait months, and many never get a vote. [U] We'll update this page if it moves. For the bigger picture on federal peptide bills, our explainer on the PEPTIDES for Veterans Act covers the House side, and our telehealth compounding explainer covers the rules already in force.
Sources (retrieved November 8, 2026)
- Congress.gov, S.3794, SAFE Drugs Act of 2026: overview, CRS summary (introduced version) and latest action [V] — https://www.congress.gov/bill/119th-congress/senate-bill/3794
- Congress.gov API, S.3794 actions (introduced Feb. 5, 2026; ordered reported July 22; reported with substitute and placed on calendar July 27, Calendar No. 524) [V] — https://api.congress.gov/v3/bill/119/s/3794/actions
- GovInfo, S.3794 Introduced in Senate (IS), bill text [V] — https://www.govinfo.gov/content/pkg/BILLS-119s3794is/html/BILLS-119s3794is.htm
- GovInfo, S.3794 Reported in Senate (RS), bill text with substitute [V] — https://www.govinfo.gov/content/pkg/BILLS-119s3794rs/html/BILLS-119s3794rs.htm
- Senate HELP Committee, executive session agenda and results, July 22, 2026 (S.3794 agreed to by roll call vote, 17-5; manager's amendment by voice vote) [V; page text read via search index, direct fetch blocked] — https://www.help.senate.gov/hearings/the-following-agenda-to-be-considered-07-22-2026
- Senate HELP Committee, "Chairman Cassidy Advances Legislation Improving Families' Access to Quality, Affordable Health Care," July 22, 2026 [V; read via search index] — https://www.help.senate.gov/rep/newsroom/press/chairman-cassidy-advances-legislation-improving-families-access-to-quality-affordable-health-care
- Office of Sen. Jim Banks, "Senate HELP Committee Advances Sen. Banks' SAFE Drugs Act," July 23, 2026 [V; read via search index] — https://www.banks.senate.gov/news/press-releases/senate-help-committee-advances-sen-banks-safe-drugs-act/
- BGR Group, Senate HELP markup summary, July 22, 2026 (Banks remarks; lists vote as 18-4) [S] — https://bgrdc.com/wp-content/uploads/2026/07/Senate-HELP-Markup_7.22.26.pdf
- Federal Register, HHS enforcement discretion policy for 503A compounding with certain peptide bulk drug substances, 91 FR 68526, FR Doc. 2026-22192, October 30, 2026, docket HHS-OASH-2026-0496 (comments close November 13, 2026) [V] — https://www.federalregister.gov/documents/2026/10/30/2026-22192/enforcement-discretion-policy-regarding-503a-compounding-using-certain-peptide-bulk-drug-substances
Cite or link to this page
Peptide Policy Watch staff. “The SAFE Drugs Act (S.3794): what the Senate compounding bill would change, and what got cut before it left committee.” Peptide Policy Watch. Published November 8, 2026. https://peptidepolicywatch.com/2026/11/08/safe-drugs-act-s3794-compounding-bill-what-it-would-change/
Spot a mistake? See how we source and our corrections policy.
Image: AI-generated. Image credits